Mankind Pharma Limited (BOM:543904)
India · Delayed Price · Currency is INR 2,469.90
-107.05 (-4.15%)
At close: Jul 31, 2026
Mankind Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 147,379 | 142,776 | 122,074 | 102,604 | 87,494 | 77,816 | |
Revenue Growth | 14.16% | 16.96% | 18.98% | 17.27% | 12.44% | 25.22% |
Cost of Revenue | 43,093 | 42,646 | 36,676 | 33,056 | 30,031 | 24,879 |
Gross Profit | 104,286 | 100,130 | 85,399 | 69,549 | 57,463 | 52,937 |
Selling, General & Admin | 41,425 | 40,124 | 34,734 | 28,830 | 23,126 | 20,934 |
Other Operating Expenses | 23,714 | 22,954 | 19,370 | 15,432 | 15,195 | 12,014 |
Operating Expenses | 74,071 | 71,939 | 60,316 | 48,047 | 41,580 | 34,614 |
Operating Income | 30,215 | 28,191 | 25,083 | 21,502 | 15,883 | 18,322 |
Interest Expense | -5,727 | -6,334 | -4,209 | -278.2 | -402.74 | -557.8 |
Interest & Investment Income | 580.5 | 580.5 | 679.1 | 396.1 | 127.67 | 129.25 |
Earnings From Equity Investments | 124.6 | 116.9 | 122.4 | 152.1 | 124.24 | 144.48 |
Currency Exchange Gain (Loss) | 700.1 | 700.1 | 195.5 | 84.4 | 104.06 | 88.45 |
Other Non Operating Income (Expenses) | -214.3 | 134.5 | 102.8 | 878.6 | 536.42 | 486 |
EBT Excluding Unusual Items | 25,679 | 23,389 | 21,974 | 22,735 | 16,372 | 18,613 |
Impairment of Goodwill | - | - | - | - | -38.52 | - |
Gain (Loss) on Sale of Investments | 1,272 | 1,272 | 1,608 | 1,295 | 374.31 | 1,129 |
Gain (Loss) on Sale of Assets | -23.1 | -23.1 | 1,614 | 4.8 | 16.65 | -37.41 |
Asset Writedown | -122.4 | -122.4 | -50.2 | -91.6 | -97.08 | -57.63 |
Other Unusual Items | -1,223 | -1,223 | 8.1 | 24.8 | 41.53 | 85.27 |
Pretax Income | 25,616 | 23,327 | 25,163 | 23,979 | 16,712 | 19,746 |
Income Tax Expense | 4,941 | 3,946 | 5,097 | 4,572 | 3,616 | 5,216 |
Earnings From Continuing Operations | 20,676 | 19,381 | 20,066 | 19,408 | 13,097 | 14,530 |
Earnings From Discontinued Operations | - | - | 45.3 | 9.8 | - | - |
Net Income to Company | 20,676 | 19,381 | 20,111 | 19,418 | 13,097 | 14,530 |
Minority Interest in Earnings | -249 | -251.7 | -201.6 | -288.7 | -278.17 | -194.81 |
Net Income | 20,427 | 19,129 | 19,910 | 19,129 | 12,819 | 14,335 |
Net Income to Common | 20,427 | 19,129 | 19,910 | 19,129 | 12,819 | 14,335 |
Net Income Growth | 7.92% | -3.92% | 4.08% | 49.23% | -10.58% | 13.28% |
Shares Outstanding (Basic) | 413 | 413 | 404 | 401 | 401 | 401 |
Shares Outstanding (Diluted) | 413 | 413 | 405 | 401 | 401 | 401 |
Shares Change | 1.36% | 2.13% | 0.88% | 0.14% | 0.00% | - |
EPS (Basic) | 49.49 | 46.35 | 49.28 | 47.75 | 32.00 | 35.78 |
EPS (Diluted) | 49.42 | 46.28 | 49.19 | 47.68 | 32.00 | 35.78 |
EPS Growth | 6.48% | -5.92% | 3.16% | 49.02% | -10.57% | 13.27% |
Free Cash Flow | - | 24,953 | 19,526 | 18,371 | 10,243 | 4,549 |
Free Cash Flow Per Share | - | 60.37 | 48.25 | 45.79 | 25.57 | 11.36 |
Gross Margin | 70.76% | 70.13% | 69.96% | 67.78% | 65.68% | 68.03% |
Operating Margin | 20.50% | 19.74% | 20.55% | 20.96% | 18.15% | 23.55% |
Profit Margin | 13.86% | 13.40% | 16.31% | 18.64% | 14.65% | 18.42% |
Free Cash Flow Margin | - | 17.48% | 16.00% | 17.90% | 11.71% | 5.85% |
EBITDA | 38,895 | 36,301 | 30,909 | 25,152 | 19,051 | 19,910 |
EBITDA Margin | 26.39% | 25.42% | 25.32% | 24.51% | 21.77% | 25.59% |
D&A For EBITDA | 8,680 | 8,110 | 5,827 | 3,649 | 3,168 | 1,588 |
EBIT | 30,215 | 28,191 | 25,083 | 21,502 | 15,883 | 18,322 |
EBIT Margin | 20.50% | 19.74% | 20.55% | 20.96% | 18.15% | 23.55% |
Effective Tax Rate | 19.29% | 16.91% | 20.26% | 19.06% | 21.63% | 26.42% |
Revenue as Reported | 150,618 | 146,364 | 127,442 | 105,407 | 88,780 | 79,776 |
Advertising Expenses | - | 7,978 | 7,554 | 6,008 | 3,737 | 4,516 |